Industry News

The Fragrance Ingredients Market is set to grow from its current market value of more than $11.5 billion to over $18.5 billion by 2024; as reported in the latest study by Global Market Insights, Inc.
Growing penetration rate of international brands, rising demand for personal care products along with growth in cosmetics industry will drive overall fragrance ingredients market demand. These compounds are mixed with personal care products to improve aroma and give freshness to a product. Growing customer spending on beauty products including creams and perfumes supported by growing ageing population may boost industry growth.

The Conference of Parties to the WHO Framework Convention for Tobacco Control (FCTC)  opens its eighth session (COP 8), with a view to defining a roadmap for strengthening and expanding the scope of the landmark global health treaty.

Continuing its efforts to promote medical technology in the country, Andhra Pradesh MedTech Zone (AMTZ) organised a mega business conference meeting ‘MedAsia Business Forum’ in the city.

RaySearch Laboratories AB (publ) has released RayCare 2B*, the latest version of the groundbreaking oncology information system (OIS). RayCare is designed to support the workflow in a modern oncology center, connecting the different oncology disciplines, boosting efficiency and ensuring optimal use of resources.

[adsense:336x280:8701650588]

U.S. Food and Drug Administration permitted marketing of ClonoSEQ assay, a next generation sequencing (NGS)-based test for minimal residual disease (MRD) in patients with acute lymphoblastic leukemia (ALL) or multiple myeloma. MRD is a measure of the amount of cancer cells remaining in a person’s bone marrow.

The U.S. Food and Drug Administration approved a new drug, Arikayce (amikacin liposome inhalation suspension), for the treatment of lung disease caused by a group of bacteria, Mycobacterium avium complex (MAC) in a limited population of patients with the disease who do not respond to conventional treatment (refractory disease).

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for the gene therapy Luxturna (voretigene neparvovec), for the treatment of adults and children suffering from inherited retinal dystrophy caused by RPE65 gene mutations, a rare genetic disorder which causes vision loss and usually leads to blindness.

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Emgality (galcanezumab), a monoclonal antibody for the prevention of migraine. Emgality belongs to a new class of medicines that work by blocking the activity of calcitonin gene-related peptide (CGRP), a molecule that is involved in migraine attacks.

Sun Pharma Advanced Research Company Ltd. announced U.S. Food and Drug Administration (USFDA) approval for the New Drug Application (NDA) of XELPROSTM (latanoprost ophthalmic emulsion) 0.005% for the reduction of elevated intraocular pressure (IOP, or pressure inside the eye) in patients with open-angle glaucoma or ocular hypertension. This approval is from Sun Pharma’s Halol (Gujarat, India) facility.

[adsense:336x280:8701650588]